Stocks in play: BriaCell Therapeutics Corp.
Announced the completion of the Phase I part of the clinical trial of its lead candidate, Bria-IMT, in combination with Incyte’s PD-1 inhibitor, retifanlimab, in advanced breast cancer. BriaCell Therapeutics Corp. shares T.BCT are trading up $0.68 at $8.60.
Read:
Highly Sought After Natural Ingredients Appearing in More Plant-Based Products Across North America
Fresher, Healthier Food Options Coming Soon to an Airplane Tray Near You
Airline Industry Wooing Back Customers with Enhanced, Healthier Menu Options
Vegetarian and Vegan Fliers Winning Important Battle Over In-Flight Menu Options
Mega Grocery Store Chains Listening to Customers’ Demands for Nutritious, Clean-Label Foods